Upstream Bio, Inc.
UPB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$255.77M
Close$
$-0.65
123.4% downside
Current Fair Value
123.4% downsideOvervalued by 123.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $255.77 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-2.66 |
| Beta | 1.39 |
| Outstanding Shares | 54,567,976 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.62 |
|---|---|
| PEG | 245.35 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.78
Consensus analyst estimateRevenue Estimate
$431,143
Consensus analyst estimateNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.73
Consensus analyst estimateRevenue Estimate
$522,455
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 93.16% |
|---|---|
| Total Invested | $9,855▼ 100.00% |
| Investors Holding | 3▼ 150.00% |
About Upstream Bio, Inc.
75 employees
CEO: E. Rand Sutherland
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features ver...